Abstract
Premature atherosclerosis is a recognized complication of systemic lupus erythematosus (SLE). Since life expectancy in SLE is improving, premature atherosclerosis is emerging as an ever more important clinical issue. Atherosclerosis begins in the pediatric age group, and interventions directed at prevention should begin in childhood as well. Possible etiologies include dyslipoproteinemia (DL) from the underlying chronic inflammatory disease or from corticosteroid therapy, hypercoagulation due to antiphospholipid antibodies or nephrotic syndrome, vasculitis, and hypertension. A relationship between DL and presence of anticardiolipin antibodies (aCL) has been reported. Dietary therapy is helpful, but many patients continue to have significant DL after both dietary modification and fish oil supplementation. Lipid lowering drugs may be indicated in this subgroup. Potential mechanisms of the DL are discussed. Other strategies to prevent atherosclerosis and its complications are reviewed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 15-19 |
| Number of pages | 5 |
| Journal | Journal of Rheumatology |
| Volume | 27 |
| Issue number | SUPPL. 58 |
| State | Published - 2000 |
Fingerprint
Keywords
- Atherosclerosis
- Childhood
- Systemic lupus erythematosus
ASJC Scopus subject areas
- Rheumatology
- Immunology
Cite this
Premature atherosclerosis in systemic lupus erythematosus. / Ilowite, Norman Todd.
In: Journal of Rheumatology, Vol. 27, No. SUPPL. 58, 2000, p. 15-19.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Premature atherosclerosis in systemic lupus erythematosus
AU - Ilowite, Norman Todd
PY - 2000
Y1 - 2000
N2 - Premature atherosclerosis is a recognized complication of systemic lupus erythematosus (SLE). Since life expectancy in SLE is improving, premature atherosclerosis is emerging as an ever more important clinical issue. Atherosclerosis begins in the pediatric age group, and interventions directed at prevention should begin in childhood as well. Possible etiologies include dyslipoproteinemia (DL) from the underlying chronic inflammatory disease or from corticosteroid therapy, hypercoagulation due to antiphospholipid antibodies or nephrotic syndrome, vasculitis, and hypertension. A relationship between DL and presence of anticardiolipin antibodies (aCL) has been reported. Dietary therapy is helpful, but many patients continue to have significant DL after both dietary modification and fish oil supplementation. Lipid lowering drugs may be indicated in this subgroup. Potential mechanisms of the DL are discussed. Other strategies to prevent atherosclerosis and its complications are reviewed.
AB - Premature atherosclerosis is a recognized complication of systemic lupus erythematosus (SLE). Since life expectancy in SLE is improving, premature atherosclerosis is emerging as an ever more important clinical issue. Atherosclerosis begins in the pediatric age group, and interventions directed at prevention should begin in childhood as well. Possible etiologies include dyslipoproteinemia (DL) from the underlying chronic inflammatory disease or from corticosteroid therapy, hypercoagulation due to antiphospholipid antibodies or nephrotic syndrome, vasculitis, and hypertension. A relationship between DL and presence of anticardiolipin antibodies (aCL) has been reported. Dietary therapy is helpful, but many patients continue to have significant DL after both dietary modification and fish oil supplementation. Lipid lowering drugs may be indicated in this subgroup. Potential mechanisms of the DL are discussed. Other strategies to prevent atherosclerosis and its complications are reviewed.
KW - Atherosclerosis
KW - Childhood
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=0034038341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034038341&partnerID=8YFLogxK
M3 - Article
C2 - 10782851
AN - SCOPUS:0034038341
VL - 27
SP - 15
EP - 19
JO - Journal of Rheumatology
JF - Journal of Rheumatology
SN - 0315-162X
IS - SUPPL. 58
ER -